Finch Therapeutics Group
VerifiedA clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs.
Launch date
Employees
Market cap
$2.9m
Net debt
($8.8m)
Enterprise valuation
$12m (Public information from May 2024)
Share price
$0.967 FNCH
Somerville Massachusetts (HQ)
Deals in current and previous year:
No columns specified